Pulmonary veno-occlusive disease: Insights from animal models.

Akiko Hata, Bengisu Gur, Jaspreet Kalra, Amit Prabhakar

Abstract readReview

In one paragraph

Review in Vascular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Akiko HataCardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA. Electronic address: akiko.hata@ucsf.edu.

Bengisu GurCardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.

Jaspreet KalraCardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.

Amit PrabhakarCardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.

Funding

Elucidating the structural insights into the BMP receptor mutations in PAHR01HL164581 · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2025 to 2025

$792k

Molecular pathogenesis of pulmonary arterial hypertensionR01HL153915 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Akiko Hata · 2023 to 2023

$780k

NHLBI NIH HHS R01 HL153915NHLBI NIH HHS R01 HL164581

6 · The paper itself

Abstract

Pulmonary veno-occlusive disease (PVOD) is a subtype of pulmonary hypertension (PH) with a poor prognosis. Patients with PVOD develop a gradual increase in pulmonary vascular resistance (PVR) and right heart failure. PVOD can occur sporadically (known as sporadic PVOD or sPVOD) or be inherited (known as heritable PVOD or hPVOD). The estimated incidence rate of PVOD is 0.1-0.5 cases per million, which is about ten times less frequent than that of pulmonary artery hypertension (PAH), a condition closely related to PVOD. Because many clinical features of PVOD overlap with those of PAH, PVOD patients are often misdiagnosed as PAH. There is a critical need for early and accurate diagnosis of PVOD and effective therapeutics for PVOD developed based on its underlying etiology. In this review, we highlight the similarities and distinctions between PAH and PVOD, recent advances in understanding the mechanisms of vascular remodeling in PVOD using animal models, and emerging therapeutic strategies specifically targeting PVOD informed by these insights.

Indexed as

Arterial PressureHypertension, PulmonaryPulmonary ArteryPulmonary VeinsPulmonary Veno-Occlusive DiseaseAnimalsDisease Models, AnimalHumansVascular RemodelingVascular ResistanceIntegrated stress responseMitomycin CProtein kinase RPulmonary artery hypertensionPulmonary hypertensionPulmonary veno-occlusive diseaseVascular remodeling

Identifiers

PMID40939813

DOI10.1016/j.vph.2025.107547

PMCPMC12758838

What Socratic holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.